HSCS HSCS
Company Profile ↓Company Overview
HSCS (HSCS) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Apr 2026 Revenue of $4.32K (-0.7% YoY); net profit $-9.14M.
- Trailing 12 Months Year-on-year growth — revenue -0.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -26.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -25.96% |
| 1 Year: | -0.71% |
Stock Price Performance
| 1 Year: | -30.91% |
| 6 Months: | -28.30% |
| 3 Months: | +12.32% |
| 1 Month: | -20.83% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.23 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -26.0% CAGR over 5 years.
- Trading 39.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jul 2021 | Oct 2021 | Jan 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Jul 2023 | Oct 2023 | Jan 2024 | Jul 2024 | Oct 2024 | Jan 2025 | Jul 2025 | Oct 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.48K | - | 2.74K | 3.20K | - | 1.95K | - | 3.90K | 14.70K | - | - | 0 | 1.90K | 2.42K | 0 |
| Gross Profit | 1.73K | - | 1.89K | 1.16K | - | 1.19K | - | 2.38K | 10.14K | - | - | 0 | 1.14K | 1.41K | 0 |
| Operating Income | -674.45K | -956.86K | -1.10M | -1.43M | -1.77M | -1.31M | -1.33M | -1.57M | -1.53M | -2.08M | -1.99M | -2.37M | -1.87M | -2.07M | -1.93M |
| Net Income | -501.85K | -1.03M | -1.24M | -1.57M | -1.81M | -1.34M | -1.37M | -1.75M | -1.64M | -2.05M | -2.08M | -2.54M | -2.05M | -2.35M | -1.99M |
| Diluted EPS | -0.15 | -0.31 | -0.37 | -0.28 | -0.22 | -0.16 | -13.23 | -15.92 | -3.01 | -2.64 | -2.27 | -2.57 | -1.58 | -0.85 | - |
| R&D Expense | 401.11K | 545.77K | 699.01K | 434.20K | 848.98K | 643.26K | 565.63K | 757.30K | 509.51K | 1.22M | 1.20M | 1.03M | 997.21K | 727.03K | 638.58K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|
| Revenue | 14.37K | 5.15K | 18.60K | 4.35K | 4.32K |
| Gross Profit | 6.48K | 2.35K | 12.52K | 2.47K | 2.55K |
| Operating Income | -4.71M | -6.11M | -6.31M | -8.35M | -8.41M |
| Net Income | -4.83M | -6.35M | -6.61M | -8.77M | -9.14M |
| Diluted EPS | -1.45 | -80.00 | -18.74 | -9.34 | - |
| R&D Expense | 3.00M | 2.46M | 2.88M | 4.39M | 2.84M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Dec 2025 | Apr 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.09M | 3.29M | 9.50M | 4.22M | 4.22M | - | 5.26M |
| Total Equity | -1.91M | -6.06M | 230.56K | 7.32M | 205.17K | 205.17K | 226.06K | 226.06K |
| Cash & Equivalents | - | 918.26K | 1.66M | 5.81M | 1.10M | 1.10M | 1.70M | 1.66M |
| Total Liabilities | - | 8.15M | 3.06M | 2.19M | 4.02M | 4.02M | - | 5.04M |
| Current Liabilities | - | 3.47M | 1.83M | 1.75M | 3.70M | 3.70M | - | 4.86M |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | -3.64M | -5.77M | -6.07M | -7.41M | -7.43M |
| Investing Cash Flow | -1.93K | -18.31K | -125.27K | -30.19K | -44.45K |
| Financing Cash Flow | 3.84M | 6.53M | 10.34M | 2.73M | 8.03M |
| Capital Expenditure | -1.93K | -18.31K | -64.45K | -3.16K | -3.55K |
| Free Cash Flow | -3.65M | -5.79M | -6.13M | -7.42M | -7.43M |
Ratios (Annual)
Figures in %.
| Metric | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|---|
| Gross Margin % | 45.1% | 45.7% | 67.3% | 56.8% | 59.1% |
| Operating Margin % | -32,765.6% | -118,698.3% | -33,902.0% | -192,013.1% | -194,787.4% |
| Net Margin % | -33,592.6% | -123,384.3% | -35,511.9% | -201,499.5% | -211,666.5% |
| ROE % | 79.7% | -2,756.1% | -90.3% | -4,272.2% | -4,044.0% |
| ROCE % | 341.0% | -420.3% | -81.4% | -1,607.2% | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HSCS
HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results
Company believes proposed Fortitude Mining Holdings business combination represents a significant value creation opportunity for the Company’s shareholders Fiscal 2026 saw the full commercial launch of the MyoVista Insights platform and sub…
Fortitude Energizes 12 MW Grand Island, Nebraska Facility, Expanding Owned-and-Operated Power Portfolio
FAIRPORT, N.Y., July 28, 2026--Fortitude expands its owned power advantage by energizing its first greenfield build at an attractive power cost.
HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K
Company believes proposed Fortitude merger represents a significant opportunity for the Company’s shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to be filed shortly, with fiscal 2026 earnings …
Zcash Miner Fortitude Merging with HeartSciences to Go Public
By Karen Roman Fortitude Mining Holdings, Inc., a Zcash mining platform, has agreed to merge with HeartSciences Inc. (Nasdaq: HSCS) in an all-stock transaction that will take the company public. The combined company is expected to trade on …
European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences’ Patent Portfolio to More Than 45 Granted Patents
Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic functionSouthlake, TX, June 11, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the …
HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
Bunkerhill Health’s FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences’ SaaS-based, recurring-revenue marketpla…
HSCS — Frequently Asked Questions
What is the current share price of HSCS?
As of 2026-08-05 17:25 PDT, HSCS trades at $2.28 on NASDAQ/NYSE. Its 52-week range is $1.67 to $3.77.
What is the P/E ratio of HSCS?
HSCS trades at a trailing price-to-earnings (P/E) ratio of -0.24.
Is HSCS a good stock to buy?
This page provides a data-driven analysis of HSCS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.